Table 1.
Modulation of miRNA expression profiles during liver regeneration
| Time after PH, h |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| miRNA | 3 | 6 | 12 | 18 | 24 | 36 | 48 | 72 | Validated targets |
| hsa-miR-105 | 1.26 | 1.42 | 1.23 | 1.34 | 2.10 | 1.53 | 1.17 | 1.72 | |
| hsa-miR-106a | 1.33 | 1.51 | 1.25 | 1.69 | 2.11 | 1.35 | 1.60 | 1.76 | VEGFA, RB1, AML1, APP |
| hsa-miR-130a | 1.46 | 1.35 | 1.53 | 1.40 | 1.71 | 2.25 | 1.88 | 2.14 | TAC1, CSF1, MAFB, MEOX2, HOXA5 |
| hsa-miR-181b | 1.08 | 0.98 | 1.57 | 2.08 | 1.58 | 1.26 | 1.94 | 1.57 | GLUR2, VSLN1, TCL1A, AICDA |
| hsa-miR-187 | 1.34 | 2.14 | 1.65 | 1.55 | 1.89 | 1.62 | 1.31 | 1.75 | |
| hsa-miR-196a | 1.23 | 1.83 | 1.64 | 1.44 | 1.68 | 2.09 | 1.13 | 1.72 | IKK2, ANXA1, HOXA7, HOXD8, HOXC7, HOXB8 |
| hsa-miR-19a | 1.27 | 1.69 | 2.50 | 1.36 | 1.52 | 1.52 | 1.44 | 1.61 | PTEN |
| hsa-miR-20a | 1.22 | 2.06 | 1.42 | 1.97 | 2.40 | 1.36 | 1.71 | 2.07 | VEGFA, AML1, E2F1, CCND1 |
| hsa-miR-20b | 1.42 | 1.68 | 1.53 | 1.95 | 2.06 | 1.70 | 1.65 | 2.05 | VEGFA |
| hsa-miR-21 | 1.55 | 1.66 | 1.62 | 2.22 | 2.10 | 2.10 | 2.13 | 2.70 | 27 validated targets |
| hsa-miR-214 | 1.03 | 1.51 | 2.02 | 1.32 | 1.47 | 1.51 | 1.26 | 1.40 | PTEN |
| hsa-miR-215 | 1.31 | 1.64 | 1.39 | 1.54 | 1.26 | 1.38 | 1.40 | 2.01 | |
| hsa-miR-365 | 1.76 | 2.13 | 1.55 | 1.11 | 1.97 | 1.60 | 1.66 | 1.69 | |
| hsa-miR-573 | 1.25 | 1.32 | 1.31 | 1.43 | 1.90 | 1.80 | 1.31 | 2.00 | |
| hsa-miR-622 | 1.01 | 1.22 | 1.00 | 1.50 | 2.02 | 1.16 | 1.25 | 1.42 | |
| hsa-miR-7 | 1.38 | 1.97 | 0.89 | 1.24 | 2.17 | 1.77 | 1.81 | 1.75 | PAK1, RAF1, IRS1, IRS2, EGFR |
| hsa-miR-768-5p | 1.20 | 2.04 | 2.28 | 1.77 | 1.97 | 1.70 | 1.57 | 1.84 | |
| hsa-miR-93 | 1.15 | 1.25 | 1.54 | 1.17 | 2.12 | 1.24 | 1.29 | 1.96 | VEGFA, E2F1, p21 |
| mmu-miR-106a | 1.64 | 1.72 | 1.53 | 1.73 | 2.23 | 1.88 | 2.17 | 2.57 | MYLIP, ARID4B |
| mmu-miR-202 | 1.26 | 1.53 | 1.38 | 1.07 | 1.41 | 3.78 | 1.35 | 1.61 | |
| mmu-miR-20b | 1.53 | 1.47 | 1.54 | 1.39 | 2.24 | 1.47 | 1.66 | 2.47 | MYLIP, ARID4B |
| mmu-miR-706 | 1.29 | 2.22 | 1.67 | 1.81 | 2.24 | 1.95 | 1.78 | 1.83 | |
| mmu-miR-720 | 1.51 | 2.20 | 1.41 | 1.07 | 1.29 | 1.37 | 1.01 | 1.61 | |
| rno-miR-20b | 1.43 | 1.39 | 1.46 | 1.42 | 2.74 | 1.69 | 1.63 | 1.91 | |
| rno-miR-333 | 1.36 | 2.48 | 1.72 | 1.43 | 1.89 | 2.20 | 1.97 | 1.52 | |
| rno-miR-7 | 1.23 | 1.93 | 0.93 | 1.18 | 1.83 | 1.74 | 1.49 | 1.70 | |
List of microRNAs (miRNAs, miRs) expressed differentially in partial hepatectomy (PH) animals compared with sham animals. Mean expression values were determined following global normalization and statistical analysis as described in materials and methods. AICDA, activation-induced cytidine deaminase; AML1, runt-related transcription factor 1; ANXA1, annexin A1; APP, amyloid precursor protein; ARID4B, AT rich interactive domain 4B (Rbp1 like); CCND1, cyclin D1; CSF1, colony stimulating factor 1; E2F1, E2F transcription factor 1; EGFR, epidermal growth factor receptor; GLUR2, glutamate receptor ionotropic AMPA 2; HOXA5; homeobox A5; HOXA7, homeobox A7; HOXB8, homeobox B8; HOXC8, homeobox C8; HOXD8, homeobox D8; IKK2, inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta; IRS1, insulin receptor substrate 1; IRS2, insulin receptor substrate 2; MAFB, v-maf musculoaponeurotic fibrosarcoma oncogene homolog B; MEOX2, mesenchyme homeobox 2; MYLIP, myosin regulatory light chain interacting protein; p21, cyclin-dependent kinase inhibitor 1A; PAK1, p21 protein (Cdc42/Rac)-activated kinase 1; PTEN, phosphatase and tensin homolog (mutated in multiple advanced cancers 1); RAF1, v-raf-1 murine leukemia viraloncogene homolog 1; RB1, retinoblastoma 1; TAC1, tachykinin precursor 1; TCL1A, T-cell leukemia/lymphoma 1A; VEGFA, vascular endothelial growth factor A; VSLN1, visinin-like 1.